5-Day radiation for breast cancer: a game changer?
NCT ID NCT06954831
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a new, ultra-short radiation schedule for women with stage I-III breast cancer who have had a lumpectomy. Instead of the usual 3-4 weeks of daily radiation, this approach delivers the entire course in just 5 days. The goal is to see if this shorter treatment is as good at preventing cancer from coming back while being more convenient and less burdensome for patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- radiation therapy
- What this could lead to
- If this works, it could offer a much shorter, more convenient radiation schedule for early-stage breast cancer patients after lumpectomy, potentially improving quality of life.
- What could go wrong
- This is a small, early-phase trial (82 participants) focused on cosmetic outcomes, not survival. The shorter schedule may not be as effective or could have different side effects compared to standard radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 82 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Age: ≥ 40 years * Female * Ability to read and understand English for questionnaires * Histologically confirmed breast cancer * Malignancy must be epithelial. Non-epithelial breast malignancies such as lymphoma or sarcoma are not allowed * Patients must have undergone breast conserving surgery. Re-excision for negative margins is allowed * Patients must have undergone surgical staging of the axilla (sentinel lymph node biopsy or axillary lymph node dissection) * Must have at least one-high risk feature that would necessitate a lumpectomy cavity boost by the treating radiation oncologist * Patient must have physician-reported "Excellent" or "Good" cosmesis post-lumpectomy and prior to radiation therapy based on the 4-point Global Cosmetic Score * Women of childbearing potential (WOCBP): negative urine or serum pregnancy test * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only) Exclusion Criteria: * Prior radiation to the region of the involved breast that in the opinion of the investigator would preclude breast irradiation * Pathologically or clinically involved regional lymph nodes necessitating comprehensive regional nodal irradiation that includes the supraclavicular fossa * Clinically significant uncontrolled illness * Stage IV breast cancer * Diagnosis of Paget's disease of the nipple * Other prior or active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Pregnant or breastfeeding * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anatomic stage I breast cancer ajcc V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
City of Hope Antelope Valley
RECRUITINGLancaster, California, 93534, United States
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
City of Hope South Pasadena
RECRUITINGSouth Pasadena, California, 91030, United States
-
City of Hope Upland
RECRUITINGUpland, California, 91786, United States
-
City of Hope at Arcadia
RECRUITINGArcadia, California, 91007, United States
-
City of Hope at Irvine Lennar
NOT_YET_RECRUITINGIrvine, California, 92618, United States
-
City of Hope at South Bay
RECRUITINGTorrance, California, 90503, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Green dye vs blue dye: which finds Cancer-Linked lymph nodes better?
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in
- Can exercise and nutrition prehab help breast cancer patients through chemo?
- Can a clotting drug cut mastectomy wound drainage?
- A simple dye might replace radioactive tracers in cancer staging
- Can new tracers make many cancers light up on scans?